bendamustine hydrochloride has been researched along with Immunoglobulin Light-chain Amyloidosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abeykoon, JP; Advani, R; Arulogun, SO; Branagan, AR; Buske, C; Cao, X; Castillo, JJ; D'Sa, S; Dimopoulos, MA; Garcia-Sanz, R; Hou, J; Kapoor, P; Kastritis, E; Kersten, MJ; LeBlond, V; Leiba, M; Matous, JV; Paludo, J; Qiu, L; San-Miguel, J; Tam, CS; Tedeschi, A; Thomas, SK; Tohidi-Esfahani, I; Treon, SP; Trotman, J; Varettoni, M; Vos, JM | 1 |
| Cantarovich, D; Delaunay, J; Kandel, C; Ville, S | 1 |
| Bhutani, D; Comenzo, RL; Lagos, GG; Landau, H; Lentzsch, S; Osman, K; Pan, S; Pregja, S; Sanchorawala, V; Zonder, JA | 1 |
| Basset, M; Bochtler, T; Foli, A; Hegenbart, U; Ho, AD; Kimmich, C; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F; Schönland, S | 1 |
| Foard, D; Fontana, M; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Lane, T; Mahmood, S; Manwani, R; Quarta, C; Rezk, T; Sachchithanantham, S; Sharpley, F; Wechalekar, AD; Whelan, C | 1 |
| Basset, M; Bochtler, T; Dittrich, T; Foli, A; Hegenbart, U; Kimmich, C; Merlini, G; Milani, P; Müller-Tidow, C; Palladini, G; Schönland, S | 1 |
2 trial(s) available for bendamustine hydrochloride and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Report of consensus panel 1 from the 11
Topics: Bendamustine Hydrochloride; Consensus; Humans; Immunoglobulin Light-chain Amyloidosis; Prospective Studies; Rituximab; Waldenstrom Macroglobulinemia | 2023 |
Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Treatment Outcome; Vomiting | 2020 |
4 other study(ies) available for bendamustine hydrochloride and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Biomarkers; Biopsy; Cell Proliferation; Humans; Immunoglobulin Heavy Chains; Immunoglobulin kappa-Chains; Immunoglobulin Light-chain Amyloidosis; Lymphoma, B-Cell, Marginal Zone; Male; Nephrotic Syndrome; Rituximab; Treatment Outcome | 2020 |
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Rate | 2017 |
Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Immunoglobulin M; Male; Middle Aged; Rituximab; Survival Rate | 2018 |
Treatment of AL amyloidosis with bendamustine: a study of 122 patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2018 |